Slow Capital Inc. Decreases Position in Insulet Co. (NASDAQ:PODD)

Slow Capital Inc. trimmed its position in Insulet Co. (NASDAQ:PODD) by 79.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,053 shares of the medical instruments supplier’s stock after selling 3,957 shares during the period. Slow Capital Inc.’s holdings in Insulet were worth $228,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently modified their holdings of PODD. Avior Wealth Management LLC raised its holdings in shares of Insulet by 3.6% during the fourth quarter. Avior Wealth Management LLC now owns 2,645 shares of the medical instruments supplier’s stock worth $574,000 after purchasing an additional 91 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Insulet by 268.8% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 53,974 shares of the medical instruments supplier’s stock valued at $11,711,000 after buying an additional 39,337 shares during the last quarter. Mackenzie Financial Corp lifted its holdings in shares of Insulet by 25.5% in the 4th quarter. Mackenzie Financial Corp now owns 7,029 shares of the medical instruments supplier’s stock valued at $1,525,000 after buying an additional 1,428 shares during the period. Lecap Asset Management Ltd. purchased a new stake in shares of Insulet in the fourth quarter worth about $1,510,000. Finally, Louisiana State Employees Retirement System acquired a new stake in Insulet during the fourth quarter worth about $911,000.

Wall Street Analyst Weigh In

PODD has been the subject of a number of analyst reports. Barclays decreased their price target on Insulet from $214.00 to $213.00 and set an “equal weight” rating for the company in a report on Monday, February 26th. Piper Sandler lowered their price target on shares of Insulet from $250.00 to $230.00 and set an “overweight” rating on the stock in a report on Friday, February 23rd. Stifel Nicolaus lifted their price objective on shares of Insulet from $163.00 to $208.00 and gave the company a “hold” rating in a report on Monday, February 5th. Robert W. Baird raised shares of Insulet from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $180.00 to $238.00 in a research note on Thursday, December 21st. Finally, JPMorgan Chase & Co. raised their target price on Insulet from $190.00 to $225.00 and gave the company an “overweight” rating in a research report on Friday, February 23rd. Four research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, Insulet has a consensus rating of “Moderate Buy” and a consensus target price of $243.21.

Insider Buying and Selling

In other news, Director Shacey Petrovic sold 11,609 shares of the company’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total value of $1,891,338.28. Following the transaction, the director now owns 2,567 shares of the company’s stock, valued at approximately $418,215.64. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.90% of the stock is currently owned by company insiders.

Insulet Trading Down 3.7 %

Shares of PODD stock opened at $166.26 on Thursday. The firm has a market capitalization of $11.64 billion, a P/E ratio of 57.13, a PEG ratio of 3.11 and a beta of 0.98. The company has a debt-to-equity ratio of 1.86, a quick ratio of 2.62 and a current ratio of 3.51. Insulet Co. has a fifty-two week low of $125.82 and a fifty-two week high of $335.91. The stock’s fifty day moving average is $175.14 and its two-hundred day moving average is $178.90.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.73. The company had revenue of $509.80 million for the quarter, compared to analyst estimates of $461.26 million. Insulet had a net margin of 12.16% and a return on equity of 32.19%. Insulet’s revenue was up 37.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.55 EPS. Research analysts expect that Insulet Co. will post 3.08 earnings per share for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.